<DOC>
	<DOCNO>NCT02784808</DOCNO>
	<brief_summary>This study design analyze frequency incidence rate pulmonary complication JIA participant receive biological DMARDs non-biologic DMARDs . The participant evidence prescription administration one biologic non-biologic DMARDs include five different treatment group . Data Thomson Reuters MarketScanÂ® Commercial Claims Medicare Supplemental Databases use estimate incidence rate pulmonary complication .</brief_summary>
	<brief_title>Retrospective Analysis Pulmonary Arterial Hypertension ( PAH ) Related Complications Juvenile Idiopathic Arthritis ( JIA ) Participants Treated With Biologic Non-biologic Disease-modifying Anti-rheumatic Drugs ( DMARDs )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Participants less ( &lt; ) 18 year age index Continuously enrol great ( &gt; ) 6 month prior index ( baseline period ) One diagnosis JIA ( 714.3 ) nondiagnostic claim either baseline period ( complete participant record prior episode index define episode baseline period ) within first 30 day follow index date Had medical pharmacy benefit plus complete data availability baseline followup period For biologic DMARD cohort , prior use qualify biologic belong biologic DMARD interest ( use available claim history ) For nonbiologic DMARD cohort , prior use nonbiologic DMARD biologic DMARD Any record rituximab use complete participant record A prior safety event baseline period</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>